Neuropathic Pain Treatment
Ketamir-2 offers a novel approach to neuropathic pain, targeting effective relief with fewer side effects and improved compliance compared to current treatments like opioids and other limited-efficacy medications
What is Ketamir?
A Novel Oral Ketamine Analog
Ketamir-2 ("Ketamir") is a novel oral ketamine analog currently under investigation for its potential to treat neuropathic pain, addressing a critical unmet need in neuropathic pain management. Additionally, Ketamir is being explored for its ability to deliver ultra-rapid antidepressant effects for patients who have not responded to conventional treatments, offering new hope for those suffering from treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDD-SI).
Rapidly Acting Antidepressant
In the past decade, ketamine has shown to be a first in class rapidly acting medication for depression, showing effects in as early as 4 hours rather than 1 – 2 weeks like conventional antidepressants
Superior Bioavailability
Oral bioavailability is predicted to be 80% based on a model of intestinal absorption and metabolism.
More Accessibility
Ketamir is being developed to potentially be delivered at home with appropriate conditions.
Analog
Its novel structure and properties are different from existing Ketamine.
Unscheduled
After making its scientific review of Ketamir, the DEA concluded that Ketamir-2 is not a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations.